Last reviewed · How we verify

CAN Community Health — Portfolio Competitive Intelligence Brief

CAN Community Health pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bictegravir, emtricitabine, and tenofovir alafenamide Bictegravir, emtricitabine, and tenofovir alafenamide marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Charlotte-Paige Rolle, MD · 1 shared drug class
  2. Midland Research Group, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CAN Community Health:

Cite this brief

Drug Landscape (2026). CAN Community Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/can-community-health. Accessed 2026-05-18.

Related